Dynavax Technologies Corporation (DVAX)

Over the past six months, Dynavax's stock has been impacted by several key events. Dynavax reported Q3 2025 EPS of $0.21, exceeding forecasts by 61.54%, with revenue reaching $94.9 million, an 18% increase year-over-year, leading to a 2.49% stock increase in aftermarket trading. Dynavax announced a new $100 million share repurchase program. Sanofi announced its intent to acquire Dynavax for $2.2 billion in cash. Dynavax's stock gained on the disclosure that another bidder was interested in the company following the Sanofi acquisition announcement. Shareholder alerts and investigations were initiated concerning the adequacy of the price and process in the proposed sale to Sanofi. The company's stock price increased by 38.97% over the last six months.

Dynavax has acknowledged seasonality in HEPLISAV-B revenue, with demand tending to slow down around the holidays. However, the company anticipates that as HEPLISAV-B continues to grow in the retail segment, this seasonality will gradually smooth out.

Dynavax Technologies Corp. is a commercial-stage biopharmaceutical company focused on developing and commercializing novel vaccines and immuno-oncology therapeutics, operating within the Pharmaceuticals & Biotech sector and the Biotechnology industry. Its primary commercial product is HEPLISAV-B, a hepatitis B vaccine approved for adults aged 18 and older. The company also produces CpG 1018, an adjuvant used in HEPLISAV-B and evaluated in other vaccine development programs. Dynavax's pipeline includes rF1V, a plague vaccine candidate in Phase 2 clinical trials, and Z-1018, an investigational shingles vaccine candidate in Phase 1/2 clinical trials for adults aged 50 and older. The company is also exploring potential expansions in COVID-19 and shingles vaccine programs and sells its products to various entities through wholesalers and specialty distributors.

Dynavax Technologies has a focused global presence, primarily in North America and Europe. Its U.S. operations are central to research, development, and commercialization efforts, while a European office in Germany supports market access and commercial activities in the region. The company's CpG 1018 adjuvant is supplied globally to partners for use in various vaccine development programs, extending its worldwide impact. Dynavax also engages in global clinical trials and collaborations. The company's common stock is traded on the Nasdaq Global Select Market (US), Deutsche Boerse AG (Germany), and the London Stock Exchange (UK).

In the past year, Dynavax's brand reputation has been influenced by both positive developments and corporate challenges. The company reported positive topline data from Part 1 of its Phase 1/2 trial for the shingles vaccine candidate, Z-1018, in October 2025. Dynavax continued to generate substantial revenue from HEPLISAV-B, with management projecting significant sales and market share growth through 2030. A protracted dispute with activist investor Deep Track Capital heated up in May 2025 ahead of the annual meeting. In November 2024, Dynavax dropped an early-stage combination vaccine for tetanus, diphtheria, and acellular pertussis after Phase 1 data did not meet expectations.

Dynavax Technologies Corporation's ownership structure includes a significant portion held by institutional funds, public and individual investors, and insiders. Institutional investors hold a substantial stake, with figures ranging from 39.27% to 96.33% of shares. Insider ownership has been reported as 2.98% or 16.31%. Major institutional owners include BlackRock, Inc., Deep Track Capital, LP, Vanguard Group Inc., State Street Corp., Millennium Management Llc, Dimensional Fund Advisors Lp, Chicago Capital, LLC, Renaissance Technologies Llc, and Geode Capital Management, Llc. Deep Track Capital, LP, an activist investor, held approximately 14.5% of Dynavax's shares and nominated candidates for the board of directors in February 2025.